糖尿病科对代谢功能障碍相关脂肪性肝病相关进展性纤维化的筛查:一项前瞻性多中心研究
该研究为前瞻性多中心研究的计划性中期分析,纳入654例2型糖尿病和/或肥胖合并MASLD患者,比较无创检查与两步法算法检测进展性纤维化高危风险的表现。FIB-4评分/VCTE算法对中/高危风险转诊表现出良好诊断性能,FIB-4评分/ELF(阈值9.8)策略阴性预测值为88-89%、阳性预测值为39-46%,FIB-4评分/2D-SWE策略阴性预测值为91%、阳性预测值为58-62%。
要点
- FIB-4评分/VCTE算法诊断性能优良,适用于糖尿病科常规筛查。
- ELF试验采用适配低阈值9.8时阴性预测值为88-89%,可作为VCTE的替代选择。
- 年龄适配的FIB-4评分阈值在所有算法中均导致阴性预测值和阳性预测值降低。
核心结论
- FIB-4评分/VCTE算法表现出优良的诊断性能,证明其适用于糖尿病科常规筛查。
- 采用适配低阈值9.8的ELF试验可作为VCTE的替代选择。
研究设计与样本
- 前瞻性多中心研究的计划性中期分析,纳入2型糖尿病和/或肥胖合并MASLD的参与者,进行包括血液无创检查、振动控制瞬时弹性成像(VCTE)和二维剪切波弹性成像(2D-SWE)的全面肝脏评估。
- 进展性纤维化风险分层由肝活检、磁共振弹性成像或VCTE ≥12 kPa的复合标准确定,取决于可获得性。
- 共纳入654例患者,其中87%患有2型糖尿病,56%为男性,74%患有肥胖。
主要发现
- 17.6%的患者具有进展性纤维化中/高危风险,9.3%的患者具有进展性纤维化高危风险。
- 各无创检查检测进展性纤维化高危风险的受试者工作特征曲线下面积:FIB-4评分0.78(95% CI 0.72-0.84),FibroMeter 0.74(0.66-0.83),FibroTest 0.78(0.72-0.85),增强肝纤维化(ELF)试验0.82(0.76-0.87),SWE 0.84(0.78-0.89)。
- FIB-4评分/ELF试验策略在阈值9.8时阴性预测值为88-89%,阳性预测值为39-46%。
- FIB-4评分/2D-SWE策略阴性预测值为91%,阳性预测值为58-62%。
- 年龄适配的FIB-4评分阈值在所有算法中均导致阴性预测值和阳性预测值降低。
关键数值与推荐
- FIB-4评分/VCTE算法对中/高危进展性纤维化风险患者转诊至肝病专科护理表现出良好诊断性能。
- ELF试验采用适配低阈值9.8时阴性预测值为88-89%、阳性预测值为39-46%。
- FIB-4评分/2D-SWE策略阴性预测值为91%、阳性预测值为58-62%。
临床怎么用
- FIB-4评分/VCTE算法可用于糖尿病科常规筛查。
- 采用适配低阈值9.8的ELF试验可作为VCTE的替代选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Screening for advanced fibrosis (AF) resulting from metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in diabetology. This study aimed to compare the performance of noninvasive tests (NITs) with that of two-step algorithms for detecting patients at high risk of AF requiring referral to hepatologists. RESEARCH DESIGN AND METHODS: We conducted a planned interim analysis of a prospective multicenter study including participants with type 2 diabetes and/or obesity and MASLD with comprehensive liver assessment comprising blood-based NITs, vibration-controlled transient elastography (VCTE), and two-dimensional shear-wave elastography (2D-SWE). AF risk stratification was determined by a composite criterion of liver biopsy, magnetic resonance elastography, or VCTE ≥12 kPa depending on availability. RESULTS: Of 654 patients (87% with type 2 diabetes, 56% male, 74% with obesity), 17.6% had an intermediate/high risk of AF, and 9.3% had a high risk of AF. The area under the empirical receiver operating characteristic curves of NITs for detection of high risk of AF were as follows: fibrosis-4 index (FIB-4) score, 0.78 (95% CI 0.72-0.84); FibroMeter, 0.74 (0.66-0.83); FibroTest, 0.78 (0.72-0.85); Enhanced Liver Fibrosis (ELF) test, 0.82 (0.76-0.87); and SWE, 0.84 (0.78-0.89). Algorithms with FIB-4 score/VCTE showed good diagnostic performance for referral of patients at intermediate/high risk of AF to specialized care in hepatology. An alternative FIB-4 score/ELF test strategy showed a high negative predictive value (NPV; 88-89%) and a lower positive predictive value (PPV; 39-46%) at a threshold of 9.8. The FIB-4 score/2D-SWE strategy had an NPV of 91% and a PPV of 58-62%. The age-adapted FIB-4 score threshold resulted in lower NPVs and PPVs in all algorithms. CONCLUSIONS: The FIB-4 score/VCTE algorithm showed excellent diagnostic performance, demonstrating its applicability for routine screening in diabetology. The ELF test using an adapted low threshold at 9.8 may be used as an alternative to VCTE.
引用
- Caussy C, Vergès B, Leleu D, et al. Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study. Diabetes Care. 2025. PMID: 39887699. doi:10.2337/dc24-2075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。